Serrapeptase: The Enzyme for Inflammation, Sinus,…

Serrapeptase has a story unlike most supplements. It was originally isolated from the bacteria (Serratia marcescens) that live in the gut of silkworms — specifically the same bacteria that allow silkworms to dissolve the cocoon they've spun around themselves. Researchers noticed this enzyme could break down non-living protein structures while leaving living tissue intact, and pharmaceutical scientists in Japan and Europe began exploring its therapeutic potential in the 1970s.

Today it's sold widely as an anti-inflammatory and "scar tissue" supplement, with claims ranging from clearing arterial plaque to dissolving scar tissue. The reality is more nuanced: there are legitimate clinical applications where serrapeptase shows real efficacy, and several claims that are unsupported or plausible but not proven.

The Mechanism: Proteolytic Activity

Serrapeptase is a serine protease — an enzyme that cleaves peptide bonds in proteins containing specific amino acid sequences. Its primary substrates are:

Fibrin: The protein that forms blood clots and scar tissue. Serrapeptase can degrade fibrin deposits in tissues, potentially reducing adhesions and aiding resolution of chronic inflammatory sites.
Bradykinin and other inflammatory peptides: Bradykinin is a potent pro-inflammatory peptide that causes vasodilation, pain sensitization, and edema. Serrapeptase directly degrades bradykinin, which is a plausible mechanism for its analgesic and anti-edema effects.
Mucus glycoproteins: Serrapeptase reduces the viscosity of mucus by cleaving the structural proteins in mucin, which explains much of the interest in its use for sinus conditions.
Damaged or dead tissue: The enzyme selectively acts on non-viable protein structures rather than healthy tissue, though this claim requires more nuanced clinical interpretation.

Enteric Coating: Why It Matters

Serrapeptase is an enzyme — like all proteins, it will be rapidly denatured and digested by stomach acid if it reaches the stomach in active form. This means that standard (non-enteric-coated) capsules are likely to be completely inactivated before reaching the small intestine, where absorption into systemic circulation can occur.

Enteric-coated serrapeptase is formulated with a pH-sensitive coating that dissolves only in the higher-pH environment of the small intestine, allowing the enzyme to survive and be absorbed intact. Nearly all of the clinical research showing systemic effects used enteric-coated formulations.

Doses in clinical trials range from 10mg to 60mg per day, with most effective protocols in the 20-40mg range. Some high-potency products are labeled in "serrapeptase activity units" (SPU or SU) rather than milligrams — look for approximately 40,000-120,000 SPU as an equivalent to the 10-30mg mass range.

Serrapeptase should be taken on an empty stomach (30-60 minutes before meals or 2 hours after) to maximize absorption and avoid interference from dietary proteins competing for absorption.

Sinusitis and Respiratory Applications

The best-evidenced application for serrapeptase is in reducing sinus symptoms and post-operative swelling. Its ability to thin and liquefy mucus by degrading mucin proteins makes it genuinely useful for conditions involving thickened mucus secretions.

A double-blind Italian trial published in the Journal of International Medical Research found serrapeptase significantly improved nasal obstruction, secretion viscosity, and nasal mucosa congestion in patients with chronic airway disease compared to placebo.

A Japanese double-blind study in chronic sinusitis patients showed that serrapeptase at 30mg/day significantly reduced secretion quantity and viscosity versus placebo, with effects measurable at 4 weeks.

In dental and oral surgery, serrapeptase has been well-studied for reducing post-operative swelling and pain. A systematic review of facial surgery trials found serrapeptase consistently reduces facial swelling and cheek swelling compared to controls, often outperforming classical NSAIDs in the studies that compared them directly (though with important methodological caveats).

Anti-Inflammatory and Pain Applications

The bradykinin-degrading mechanism gives serrapeptase a plausible basis for pain and inflammation reduction, and several small trials have examined this. A study in carpal tunnel syndrome found serrapeptase superior to placebo for symptom relief. Trials in chronic inflammatory conditions including rheumatoid arthritis and ankle sprains have shown positive results.

However, the evidence base here is weaker than for sinus/mucus applications. Many trials are small, poorly controlled, or published in regional journals with limited peer review. The effect sizes that have been reported are meaningful, but the confidence intervals are wide.

For inflammatory conditions, serrapeptase should be considered a supporting therapy rather than a primary treatment, and the evidence doesn't yet support strong recommendations for most pain conditions over established options.

Arterial Plaque and Scar Tissue: Proceed With Skepticism

Among the more dramatic claims made for serrapeptase is that it can "dissolve" arterial plaques and "eat away" scar tissue. This derives from its mechanism of degrading fibrin and non-living protein structures.

The reality is that arterial plaque is a complex structure containing calcium, lipids, foam cells, and fibrous tissue — not simply a fibrin deposit that a proteolytic enzyme can dissolve. There are no human clinical trials demonstrating meaningful plaque regression with serrapeptase, and this claim should be treated as biologically implausible at standard supplement doses.

Scar tissue dissolution is more plausible mechanistically but also not supported by robust clinical data. There are anecdotal reports and some open-label case series, but no randomized controlled evidence.

Blood Thinning Caution

This is the most important safety consideration with serrapeptase. Because it degrades fibrin and has anticoagulant-adjacent activity, serrapeptase carries a real risk of increased bleeding tendency, particularly when combined with:

Anticoagulants (warfarin, heparin, apixaban, rivaroxaban, dabigatran)
Antiplatelet drugs (aspirin, clopidogrel, ticagrelor)
Other fibrinolytic supplements (nattokinase, high-dose fish oil, bromelain, vitamin E at high doses)

Do not combine serrapeptase with blood thinners without medical supervision. For individuals scheduled for surgery, serrapeptase should be stopped at least 1-2 weeks before the procedure due to potential effects on coagulation and wound healing.

Additional Safety Notes

Serrapeptase has been used extensively in clinical practice in Japan and European countries and has a reasonably well-established safety profile at standard doses. Serious adverse events are rare but include:

Pneumonitis and interstitial lung disease: Several case reports in Japan of eosinophilic pneumonia associated with serrapeptase. This appears rare but is a documented adverse event.
Skin reactions: Occasional reports of rash and skin photosensitivity.
GI symptoms: Mild nausea or stomach upset, particularly if taken without adequate empty-stomach conditions.

The Bottom Line

Serrapeptase has legitimate clinical evidence for sinus symptom relief, mucus viscosity reduction, and post-surgical swelling reduction — and the mechanism for these effects is well understood. Pain and anti-inflammatory applications have supporting evidence but the quality and consistency of trials is lower.

Always use enteric-coated formulations at 20-40mg (or equivalent SPU dosing) on an empty stomach. The blood-thinning concern is real and must be respected — avoid combining with anticoagulants. Disregard claims about dissolving arterial plaque or reversing scar tissue; the evidence simply isn't there.

See how serrapeptase interacts with your other supplements. Use Optimize free.

Serrapeptase: What It Is and How It Supports Cardiovascular Health

Serrapeptase: The Enzyme for Inflammation, Sinus, and Pain